Cardiometabolic Risk in India - ECAB

Download or Read eBook Cardiometabolic Risk in India - ECAB PDF written by KM Prasanna Kumar and published by Elsevier Health Sciences. This book was released on 2009-02-15 with total page 120 pages. Available in PDF, EPUB and Kindle.
Cardiometabolic Risk in India - ECAB
Author :
Publisher : Elsevier Health Sciences
Total Pages : 120
Release :
ISBN-10 : 9788131232101
ISBN-13 : 8131232107
Rating : 4/5 (01 Downloads)

Book Synopsis Cardiometabolic Risk in India - ECAB by : KM Prasanna Kumar

Book excerpt: Cardiometabolic disease is the leading cause of death in many parts of the world. There are many potentially modifiable and non-modifiable risk factors associated with the same. Although with the recent advances in management and preventive strategies the mortality rates have reduced, but no patient actually achieves an adequate control of the CVD risk factors with the declining quality of life. In addition, growing obesity and DM in younger age groups has further undermined the improvements achieved in CVD. Diabetes and CVD share a "common soil" in their etiology and the causative factors for these diseases are termed as "cardiometabolic risk factors." Cardiometabolic risk (CMR) is the global risk of developing type 2 diabetes and CVD. CMR factors include overweight or obesity, high blood glucose, HTN, dyslipidemia, inflammation and hypercoagulation, physical inactivity, smoking, age, race and ethnicity, gender, and family history. Among these, age, race/ethnicity, gender, and family history are non-modifiable risk factors. The remaining are modifiable risk factors and closely interrelated. Recently, systematic prospective studies have shown evidences that moderate lifestyle modifications help in reducing the metabolic risk factors. The major principles include cessation of smoking, enhanced physical activity, and reduction of excess weight. Healthy diet also has a major role in controlling overweight and maintaining ideal weight. Each of the risk factors poses a danger to good health; the propensity increases with multiple risk factors. It is also shown that the CMR factors tend to cluster as the metabolic syndrome. This book is designed to address such questions with supportive typical clinical scenarios, with which all readers will be able to identify. Thus it provides an excellent opportunity to widen one’s perspective in this area.


Cardiometabolic Risk in India - ECAB Related Books

Cardiometabolic Risk in India - ECAB
Language: en
Pages: 120
Authors: KM Prasanna Kumar
Categories: Medical
Type: BOOK - Published: 2009-02-15 - Publisher: Elsevier Health Sciences

DOWNLOAD EBOOK

Cardiometabolic disease is the leading cause of death in many parts of the world. There are many potentially modifiable and non-modifiable risk factors associat
Insulin Resistance - ECAB
Language: en
Pages: 131
Authors: Gita Ganguly Mukherjee
Categories: Medical
Type: BOOK - Published: 2010-10-26 - Publisher: Elsevier Health Sciences

DOWNLOAD EBOOK

The insulin resistance syndrome can be defined as insulin resistance, compensatory hyperinsulinemia, and their associated co-morbidities. Clinically, the term i
Hotspots in Diabetes - ECAB
Language: en
Pages: 129
Authors: Ambady Ramachandran
Categories: Medical
Type: BOOK - Published: 2013-07-12 - Publisher: Elsevier Health Sciences

DOWNLOAD EBOOK

Diabetes is one of the most important non-communicable lifestyle diseases. Diabetes is a multifaceted disorder which possibly influences and impacts body pathop
Glycemic Monitoring - ECAB
Language: en
Pages: 96
Authors: Rangasamy V. Jayakumar
Categories: Medical
Type: BOOK - Published: 2009-03-15 - Publisher: Elsevier Health Sciences

DOWNLOAD EBOOK

Diabetes is a chronic disease that is reaching an epidemic proportion in many parts of the world. Despite the high incidence of diabetes, individuals diagnosed
Oral Hypoglycemic Agents - ECAB
Language: en
Pages: 111
Authors: Abdul Hamid Zargar
Categories: Medical
Type: BOOK - Published: 2009-09-25 - Publisher: Elsevier Health Sciences

DOWNLOAD EBOOK

Even though we have many advances in the development of oral hypoglycemic agents, an ideal drug for treating type 2 diabetes is still a distant reality. Today,